Becton Dickinson Surgery Revenue Falls By 70%

10 May 2020

Becton Dickinson (BD) saw their surgery revenue decline by 50-70%1 in April, due to the novel coronavirus (COVID-19)2 forcing elective surgical procedures to be deferred

Chief Financial Officer Chris Reidy3 commented that surgery revenues in China are still only at 50% of pre-pandemic expectation and estimated the losses at around $60 million in BD’s surgery business and $50 million in their peripheral intervention business4

Despite launching new diagnostic kits to identify COVID-19, and ramping up production in response to the pandemic5, Reidy estimated that overall COVID-19 had negatively impacted BD by $240 million in April

BD now joins a score of other med tech companies to report losses in FY20206